Brickell Biotech
NASDAQ:BBIBrickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
WisdomTree U.S. LargeCap Fund
NYSEARCA:EPSWisdomTree Earnings 500 Fund (the Fund) seeks investment results that correspond to the price and yield performance of the WisdomTree Earnings 500 Index (the Index). The Index is a fundamentally weighted index that measures the performance of earnings-generating companies within the large-capitalization segment of the United States stock market. Companies in the Index are incorporated and listed in the United States, and have generated positive cumulative earnings over their most recent four fiscal quarters prior to the Index measurement date. The Index consists of the 500 largest companies ranked by market capitalization in the WisdomTree Earnings Index. The Index is earnings-weighted in December of each year to reflect the proportionate share of the aggregate earnings each component company has generated. Companies with greater earnings generally have larger weights in the Index. The Fund's investment advisor is WisdomTree Asset Management, Inc.
Nuveen Credit Opportunities 2022 Target Term Fund
NASDAQ:JCONuveen Credit Opportunities 2022 Target Term Fund is a closed ended fixed income mutual fund launched by Nuveen Investments, Inc. The fund is co-managed by Nuveen Fund Advisors, LLC and Symphony Asset Management. It invests in fixed income markets of the United States. The fund primarily invests in corporate debt securities including bonds and senior loans. It invests in investment grade fixed income securities rated BBB- or higher by S&P with a maturity date on June 1, 2022. The fund employs a fundamental analysis with bottom-up stock picking approach while focusing on factors such as sector dynamics, company business models and asset quality and analysis of the relative value to create its portfolio. Nuveen Credit Opportunities 2022 Target Term Fund was formed on September 28, 2016 and is domiciled in the United States.
Jadestone Energy
CVE:JSEJadestone Energy Inc., together with its subsidiaries, engages in the production, development, and exploration and appraisal activities in Australia, Indonesia, Vietnam, and the Philippines. Its two producing assets include the Stag Oilfield located in the Carnarvon Basin, offshore Western Australia with a total proved and probable reserves of 17.1 million barrels of oil; and the Ogan Komering production sharing contract located onshore South Sumatra, Indonesia. The company's portfolio also comprises approximately 44,000 square kilometers of exploration and pre-development acreage across the Philippines, Vietnam, and Indonesia. Jadestone Energy Inc. is headquartered in Singapore.